Mineralys Therapeutics, Inc. (MLYS) Ownership
MLYS ownership summary
as of October 17, 2026- Institutions
- 117.5% of shares outstanding
- Insiders
- 0.70% of shares outstanding
- Shares outstanding
- 88.4M
- Float
- 66.6M shares available to trade
- Short interest
- 10.57% 7.8M shares short
- Days to cover
- 5.22 short interest down 15.0% vs prior month
- Institutions 117.48%
- Insiders 0.70%
MLYS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Catalys Pacific LLC | 8.94% | 7.9M | $160.4M | — | June 30, 2026 |
| 2 | RA Capital Management, LLC | 8.70% | 7.7M | $156.2M | — | June 30, 2026 |
| 3 | BlackRock Inc | 6.66% | 5.9M | $119.5M | +1.4M (+31.4%) | June 30, 2026 |
| 4 | Samsara BioCapital, LLC | 6.64% | 5.9M | $119.2M | — | June 30, 2026 |
| 5 | FMR Inc | 5.10% | 4.5M | $91.6M | −349,415 (−7.2%) | June 30, 2026 |
| 6 | State Street Corp | 4.68% | 4.1M | $84.1M | +1.2M (+41.1%) | June 30, 2026 |
| 7 | Deerfield Management Co | 4.48% | 4.0M | $80.3M | +4.0M (0.0%) | June 30, 2026 |
| 8 | Vanguard Capital Management, LLC | 3.12% | 2.8M | $56.0M | +302,407 (+12.3%) | June 30, 2026 |
| 9 | LAURION CAPITAL MANAGEMENT LP | 2.83% | 2.5M | $50.9M | +274,112 (+12.3%) | June 30, 2026 |
| 10 | T. Rowe Price Associates, Inc. | 2.56% | 2.3M | $45.9M | +919,163 (+68.4%) | June 30, 2026 |
| 11 | Orbimed Advisors LLC | 2.39% | 2.1M | $42.8M | +57,400 (+2.8%) | June 30, 2026 |
| 12 | Capital World Investors | 2.26% | 2.0M | $40.6M | +1.6M (+401.7%) | June 30, 2026 |
| 13 | Armistice Capital, LLC | 1.96% | 1.7M | $35.2M | +560,000 (+47.6%) | June 30, 2026 |
| 14 | Nantahala Capital Management, LLC | 1.86% | 1.6M | $33.3M | +745,481 (+83.2%) | June 30, 2026 |
| 15 | Franklin Templeton Inc | 1.85% | 1.6M | $33.2M | −149,142 (−8.4%) | June 30, 2026 |
| 16 | Andera Partners | 1.80% | 1.6M | $32.3M | — | June 30, 2026 |
| 17 | Geode Capital Management, LLC | 1.79% | 1.6M | $32.2M | +283,191 (+21.8%) | June 30, 2026 |
| 18 | SR ONE CAPITAL MANAGEMENT, LP | 1.77% | 1.6M | $31.7M | — | June 30, 2026 |
| 19 | Bank of America Corp | 1.70% | 1.5M | $30.6M | +405,175 (+36.8%) | June 30, 2026 |
| 20 | Sphera Funds Management Ltd. | 1.66% | 1.5M | $29.8M | +130,000 (+9.7%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 11.8M shares and 2 cut 499K.
MLYS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.23% | 2.0M | $40.0M | — | August 31, 2026 |
| 2 | American Funds SMALLCAP World A | 2.20% | 1.9M | $39.5M | +1.5M (+388.3%) | June 30, 2026 |
| 3 | iShares Russell 2000 ETF | 1.79% | 1.6M | $32.2M | −18,240 (−1.1%) | September 30, 2026 |
| 4 | State Street® SPDR® S&P® Biotech ETF | 1.67% | 1.5M | $30.0M | −28,250 (−1.9%) | September 30, 2026 |
| 5 | Polar Capital Biotech S Inc | 1.52% | 1.3M | $27.3M | — | August 31, 2026 |
| 6 | Fidelity Select Health Care | 1.33% | 1.2M | $24.0M | — | August 31, 2026 |
| 7 | HBM Healthcare Investments AG Ord | 1.29% | 1.1M | $23.1M | +355,433 (+45.5%) | June 30, 2026 |
| 8 | Worldwide Healthcare Ord | 1.28% | 1.1M | $23.0M | — | June 30, 2026 |
| 9 | Pictet-Biotech P USD | 1.06% | 940K | $19.1M | −3,810 (−0.4%) | June 30, 2026 |
| 10 | Franklin Biotechnology Discv A(acc)USD | 1.03% | 908K | $18.4M | −75,650 (−7.7%) | August 31, 2026 |
| 11 | American Century Small Cap Growth Inv | 0.90% | 792K | $16.1M | +112,781 (+16.6%) | June 30, 2026 |
| 12 | T. Rowe Price New Horizons | 0.85% | 755K | $15.3M | −30,836 (−3.9%) | August 31, 2026 |
| 13 | Candriam Eqs L Biotech C USD Cap | 0.75% | 660K | $13.4M | +123,517 (+23.0%) | March 31, 2026 |
| 14 | Strategic Advisers Fidelity US TtlStk | 0.71% | 630K | $12.8M | — | August 31, 2026 |
| 15 | Fidelity Small Cap Index | 0.71% | 628K | $12.7M | +5,392 (+0.9%) | July 31, 2026 |
| 16 | Fidelity Advisor Health Care I | 0.68% | 600K | $12.2M | — | August 31, 2026 |
| 17 | iShares Russell 2000 Growth ETF | 0.65% | 573K | $11.6M | −726 (−0.1%) | September 30, 2026 |
| 18 | T. Rowe Price Integrated US Sm Gr Eq | 0.61% | 539K | $10.9M | — | August 31, 2026 |
| 19 | Franklin Biotechnology Discovery A | 0.56% | 495K | $10.0M | −38,987 (−7.3%) | August 31, 2026 |
| 20 | iShares Biotechnology ETF | 0.54% | 473K | $9.6M | −3,584 (−0.8%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
MLYS insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-17 | David Malcom Rodman | Sell | $31.33 | 416 | $13,033 |
| 2026-04-15 | David Malcom Rodman | Sell | $27.66 | 6,348 | $175,586 |
| 2026-04-13 | David Malcom Rodman | Sell | $26.54 | 14,058 | $373,099 |
| 2026-04-13 | Jon Congleton | Sell | $26.83 | 15,730 | $422,036 |
| 2026-04-09 | David Malcom Rodman | Sell | $27.38 | 2,170 | $59,415 |
| 2026-03-31 | Daphne Karydas | Sell | $25.00 | 3,000 | $75,000 |
| 2026-03-31 | Jon Congleton | Sell | $26.27 | 75,000 | $2.0M |
| 2026-03-27 | Ra Capital Management, L.P. | Buy | $23.67 | 310,700 | $7.4M |
| 2026-03-13 | David Malcom Rodman | Sell | $26.26 | 14,058 | $369,163 |
| 2026-03-12 | David Malcom Rodman | Sell | $27.37 | 6,348 | $173,745 |
| 2026-03-09 | David Malcom Rodman | Sell | $26.84 | 2,171 | $58,270 |
| 2026-02-17 | David Malcom Rodman | Sell | $27.59 | 417 | $11,505 |
| 2026-02-13 | David Malcom Rodman | Sell | $27.44 | 14,055 | $385,669 |
| 2026-02-12 | David Malcom Rodman | Sell | $28.99 | 6,349 | $184,058 |
| 2026-02-09 | David Malcom Rodman | Sell | $30.21 | 2,171 | $65,586 |
| 2026-01-20 | David Malcom Rodman | Sell | $32.10 | 416 | $13,354 |
| 2026-01-14 | David Malcom Rodman | Sell | $32.61 | 11,367 | $370,678 |
| 2026-01-13 | David Malcom Rodman | Sell | $32.75 | 7,709 | $252,470 |
| 2026-01-12 | Adam Scott Levy | Sell | $32.14 | 10,758 | $345,762 |
| 2026-01-12 | Jon Congleton | Sell | $32.62 | 16,236 | $529,618 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
MLYS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns MLYS
Institutional investors own 117.5% of Mineralys Therapeutics's shares and insiders 0.70%. The largest holder is Catalys Pacific LLC with 8.94% of the shares (7.9M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 2 reduced their stake in the latest filings. Short interest is 10.57% of the float, or 5.22 days of average trading volume. The share count rose 1,510.9% since 2020.
Related: MLYS analyst forecast, MLYS key metrics. See the MLYS stock overview for the latest quote and news.
MLYS ownership FAQ
Who owns the most Mineralys Therapeutics stock?
The largest shareholders of Mineralys Therapeutics are Catalys Pacific LLC (8.94%), RA Capital Management, LLC (8.70%), BlackRock Inc (6.66%), Samsara BioCapital, LLC (6.64%), FMR Inc (5.10%).
What percentage of Mineralys Therapeutics is owned by institutions?
Institutions hold 117.5% of Mineralys Therapeutics's shares outstanding; insiders hold 0.70%.
Which funds own Mineralys Therapeutics?
The largest fund holders of Mineralys Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.23%), American Funds SMALLCAP World A (2.20%), iShares Russell 2000 ETF (1.79%), State Street® SPDR® S&P® Biotech ETF (1.67%), Polar Capital Biotech S Inc (1.52%).
What is Mineralys Therapeutics's short interest?
7.8M shares of Mineralys Therapeutics were sold short, 10.57% of the float; at the average daily volume it would take 5.22 days to cover.
Are insiders buying or selling Mineralys Therapeutics?
Of the latest 20 reported insider transactions in Mineralys Therapeutics (since January 12, 2026), 1 were purchases and 19 were sales.
How many shares of Mineralys Therapeutics are outstanding?
Mineralys Therapeutics has 88.4M shares outstanding, of which 66.6M are in the public float.